Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
obesity drugs
Biotech
Lilly's amylin data impress with 11% weight loss, tolerability
Eli Lilly impressed analysts with results that point to the potential for the drug candidate to form part of a market-leading Zepbound combination.
Nick Paul Taylor
Jun 16, 2025 4:55am
Novo Nordisk inks $812M Deep Apple deal to pursue obesity target
Jun 11, 2025 7:00am
Metsera posts amylin data, eyes monthly GLP-1 combo
Jun 9, 2025 7:00am
Eli Lilly taps Camurus' tech to advance long-acting obesity meds
Jun 3, 2025 5:04pm
BioAge inks option agreement for Chinese biotech's obesity asset
Jun 3, 2025 2:06pm
Fierce Pharma
Novo's longtime CEO Lars Fruergaard Jørgensen to step down
May 16, 2025 9:41am
